Spinal Muscular Atrophy Type I Clinical Trial
Official title:
Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)
This is a multi-center trial to test safety and evaluate early treatment intervention with valproic acid and carnitine in moderating SMA symptoms of Type I infants.
Spinal muscular atrophy (SMA) is a genetic disorder that results in severe muscle weakness.
It is one of the most common conditions causing muscle weakness in children. Patients with
SMA most often develop weakness as babies or young children. Most people with SMA gradually
lose muscle strength and abilities over time. Babies with the severe infantile form of SMA,
SMA type I, usually lose abilities and strength quickly over a few weeks or months.
Valproic acid (VPA) is a medicine that has been used for many years to treat patients with
epilepsy. Recent research suggests that VPA may be able to upregulate expression of a backup
copy of the SMN gene in SMA patient cell lines. In addition, some preliminary data suggests
it may prolong survival in animal models of SMA. Because VPA can deplete carnitine in
children with SMA Type I, carnitine is added to help prevent possible toxicity.
In this multi-center trial, we will evaluate the effects of VPA/carnitine on infants with
SMA type I. A variety of outcome measures, including assessment of safety, will be performed
at each study visit to follow the course of the disease. The protocol includes two baseline
visits over a period of two weeks, two clinical assessments on medication at 3 and 6 months,
and then 6 months additional followup via telephone. Total duration of the study will be
approximately 12 months.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05715749 -
Body Weight Support Harness System in Spinal Muscular Atrophy
|
N/A | |
| Recruiting |
NCT05878418 -
The Effect of Spinal Orthosis on the Development of Scoliosis and Chest Deformity in Type I Spinal Muscular Atrophy
|
N/A | |
| Recruiting |
NCT05614531 -
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type 1
|
Phase 1/Phase 2 | |
| Completed |
NCT03837184 -
Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies
|
Phase 3 | |
| Terminated |
NCT00439218 -
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04042025 -
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
|
Phase 3 |